| アブストラクト | OBJECTIVE: This study aimed to assess the latent threat of depression and suicide/self-injury associated with the combination of glucagon-like peptide-1 agonists (GLP-1RAs) and metformin versus GLP-1RAs monotherapy, through analyzing the data from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). METHODS: We systematically searched the FAERS database for reports on the concomitant use of GLP-1RAs and metformin compared with GLP-1RAs monotherapy in diabetic or obese patients. Reports were categorized on the basis of the medical dictionary for regulatory activities (MedDRA) terminology. Reporting odds ratio (ROR) of >/=1, >/=3 cases, and information component (IC)025 > 0 were considered to be significant. RESULTS: The addition of metformin increased the risk of death (38.5% vs 12.4%, P<0.001) and hospitalization-initial or prolonged (13.5% vs 7.2%, P=0.035) attributed to suicide/self-injury received GLP-1RAs. Furthermore, GLP-1RAs combined with metformin was disproportionately linked to a higher incidence of suicide/self-injury (ROR=50.89, 95%CI 40.79-63.48, IC025=5) and depression (except suicide and self-injury) (ROR=17.28, 95%CI 13.65-21.87, IC025=3.64) when compared with GLP-1RAs monotherapy. The addition of metformin was confirmed to have shorter intervals to time-to-onset (TTO) than GLP-1RAs monotherapy. CONCLUSIONS: The combination of GLP-1RAs and metformin is linked to higher risk of depression and suicide/self-injury compared with GLP-1RAs monotherapy. |
|---|
| ジャーナル名 | Endocrine connections |
|---|
| Pubmed追加日 | 2026/2/11 |
|---|
| 投稿者 | Ji, Wenjun; Ma, Ying; Fang, Jie; Chen, Linwei |
|---|
| 組織名 | Department of Pharmacy, the Affiliated Taizhou People's Hospital of Nanjing;Medical University, Taizhou 225300, China.;Department of Pharmacy, Ruijin Hospital, Shanghai Jiao Tong University School of;Medicine, Shanghai 200001, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41670433/ |
|---|
